Orbital High-Throughput Screener (OHTS)
Space station lab testing thousands of drug samples at once
Exobiosphere
Luxembourg and Los Angeles startup building an automated drug-screening lab for the ISS that tests thousands of samples on disease models grown in microgravity. Its first ISS campaigns are booked for 2027 through Voyager. (1 product in the atlas)
Products, by altitude
Low Earth orbit · 160–2,000 km
In development ![]()
Known rounds
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Government grant (non-dilutive) | €1M1 |
Milestones
- Oct 2026 Exobiosphere and Axiom Space signed a memorandum of understanding on drug discovery in space. Company statement2
- May 2026 Voyager Technologies signed on as mission integrator to install Exobiosphere's Orbital High-Throughput Screener on the ISS. Company statement3
- Apr 2026 The European Space Agency awarded Exobiosphere a EUR 200,000 contract for space-enabled bioengineering work. Company statement4
Sources
Updated Oct 22, 2026 · How we source facts · Suggest a correction